VISCHER assisted Polyneuron Pharmaceuticals AG, a Basel based spin-off company from the University of Basel, developing carbohydrate-based drugs for the targeted treatment of autoimmune disorders affecting the nervous system. Polyneuron’s Antibody-Catch® technology platform enables the rational design of immunomodulatory compounds acing as molecular scavengers for disease-causing autoantibodies. This CHF 3 million financing round was led by EVA Basel and Zürcher Kantonalbank, including other private investors. The team at VISCHER was led by Matthias Staehelin (Partner) with Moritz Jäggy (Senior Associate), both Corporate.